JeanLuc Belingard - Laboratory Independent Director
| LH Stock | USD 241.16 0.99 0.41% |
Director
Mr. JeanLuc Belingard is Independent Director of the Company. He has served as a director of the Company since April 28, 1995. From 2011 to December 2017, Mr. Blingard served as Chairman of bioMrieux, the worldwide leader of the IVD microbiology segment and a nonU.S. public company since 2010. Mr. Blingard continues to serve on the board of directors of bioMrieux and as Vice President of Institut Mrieux. Prior to serving as Chairman, Mr. Blingard had served as Chief Executive Officer of bioMrieux from July 2011 to April 2014. Mr. Blingard retired as Chairman and Chief Executive Officer of Ipsen SA, a diversified French healthcare holding company, on November 22, 2010. He had served in that position since 2002. Prior to this position, Mr. Blingard was Chief Executive Officer from 1999 to 2001 of bioMrieuxPierre Fabre, a diversified French healthcare holding company, where his responsibilities included the management of that companys worldwide pharmaceutical and cosmetic business. From 1990 to 1999, Mr. Blingard was Chief Executive Officer of Roche Diagnostics and a member of the Hoffman La Roche group Executive Committee. Mr. Blingard is a director of the following nonUS public companies Stallergenes Greer since 2011, Transgene SA since 2013, and Lupin Limited . Mr. Blingard holds directorships at various Institut Mrieux Group companies, in particular at Institut Mrieux, the Groups parent company. Mr. Blingard serves on the advisory board of Laboratoire Pierre Fabre S.A. since 2013, which is owned by The Pierre Fabre Foundation, a governmentrecognized public organization. Mr. Blingard is also a member of the Bill and Melinda Gates Foundation CEO Roundtable. Mr. Blingard was Chairman of FEFIS, the French Federation of Health Industries since 2016, and, since January 2017, he was a member of the Conseil National de lIndustrie chaired by the French government. since 1995.
| Age | 72 |
| Tenure | 29 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0396 % which means that for every $100 of assets, it generated a profit of $0.0396. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0543 %, which means that it produced $0.0543 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.05. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark McClellan | Cigna Corp | 57 | |
| Frank Bisignano | Humana Inc | 62 | |
| Roman Martinez | Cigna Corp | 71 | |
| Lori Robinson | Centene Corp | 62 | |
| Robert Ditmore | Centene Corp | 86 | |
| Tommy Thompson | Centene Corp | 78 | |
| Jessica Blume | Centene Corp | 66 | |
| Gail Wilensky | UnitedHealth Group Incorporated | 76 | |
| Michele Hooper | UnitedHealth Group Incorporated | 68 | |
| Eric Foss | Cigna Corp | 62 | |
| Glenn Renwick | UnitedHealth Group Incorporated | 64 | |
| Kimberly Ross | Cigna Corp | 56 | |
| Eric Wiseman | Cigna Corp | 65 | |
| Donna Zarcone | Cigna Corp | 63 | |
| William Trubeck | Centene Corp | 74 | |
| David Jones | Humana Inc | 71 | |
| Valerie Rice | UnitedHealth Group Incorporated | 58 | |
| John Noseworthy | UnitedHealth Group Incorporated | 69 | |
| Karen Katz | Humana Inc | 64 | |
| James OBrien | Humana Inc | 66 | |
| William McDonald | Humana Inc | 64 | |
Management Performance
| Return On Equity | 0.0543 | ||||
| Return On Asset | 0.0396 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Akinbolade Oyegunwa, Executive Officer | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Jonathan DiVincenzo, Executive International | ||
| Kerrii Anderson, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Enterprise VP | ||
| John Treadwell, Vice Initiatives | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| JeanLuc Belingard, Independent Director | ||
| Sandra JD, Chief VP | ||
| Kathryn Wengel, Independent Director | ||
| Peter Neupert, Lead Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| Richelle Parham, Independent Director | ||
| Robert Williams, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Garheng Kong, Independent Director | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0543 | ||||
| Return On Asset | 0.0396 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 26.46 B | ||||
| Shares Outstanding | 83.64 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 94.80 % | ||||
| Number Of Shares Shorted | 2.23 M | ||||
| Price To Earning | 12.69 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 5.28 | Revenue Per Share 151.028 | Quarterly Revenue Growth 0.074 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.